Vanda Pharmaceuticals’ (VNDA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a $13.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Vanda Pharmaceuticals’ FY2025 earnings at ($1.55) EPS and FY2025 earnings at ($1.55) EPS.

A number of other equities analysts have also weighed in on the stock. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Vanda Pharmaceuticals Stock Up 5.9%

Vanda Pharmaceuticals stock opened at $4.16 on Wednesday. The company has a market cap of $245.17 million, a P/E ratio of -13.00 and a beta of 0.69. The business has a 50-day simple moving average of $4.44 and a two-hundred day simple moving average of $4.63. Vanda Pharmaceuticals has a 52-week low of $3.81 and a 52-week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The firm had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Research analysts anticipate that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $5.02 per share, for a total transaction of $50,200.00. Following the acquisition, the chief executive officer now owns 2,285,731 shares in the company, valued at approximately $11,474,369.62. The trade was a 0.44% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders acquired 32,000 shares of company stock worth $151,180. 10.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently made changes to their positions in the company. Millennium Management LLC boosted its stake in Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after buying an additional 1,470,898 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Vanda Pharmaceuticals by 34.3% during the 1st quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 14,232 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 18.9% during the 1st quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,210 shares during the last quarter. Stonepine Capital Management LLC raised its stake in Vanda Pharmaceuticals by 40.6% during the first quarter. Stonepine Capital Management LLC now owns 35,148 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 10,148 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in Vanda Pharmaceuticals during the first quarter valued at $170,000. 88.14% of the stock is owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.